VRTX analyst scorecard · Vertex Pharmaceuticals
48 rating actions on VRTX in the last 12 months. Of 83 price targets that resolved, 32 were reached while they stood, 46 were replaced by the same firm first, and 5 fell short at their deadline. Ratings: 79% Buy-type, 19% Hold-type, 2% Sell-type. Consensus target $571, 6% above the last close.
Checked through 2026-10-29 · last close $539.54 (2026-10-29). Rebuilt every morning.
What the Holds say: 9 Hold-type ratings on VRTX in the last 12 months carried a median target -2% from the price on the day; 56% sat below it.
The 7 upgrades on VRTX came after an average +2.9% move in the 30 days before them.
Firm by firm
| Firm | Latest rating | Date | Latest target | Targets reached | Replaced early | Resolved | Ratings vs sector |
|---|---|---|---|---|---|---|---|
| UBS | Buy | 2026-09-28 | $615 | 0 | 6 | 6 | 0 of 1 |
| Barclays | Overweight | 2026-08-05 | $617 | 1 | 4 | 5 | — |
| RBC Capital | Outperform | 2026-10-08 | $576 | 3 | 7 | 10 | — |
| Morgan Stanley | Overweight | 2026-05-05 | $616 | 1 | 5 | 6 | — |
| Bernstein | Outperform | 2026-05-05 | $572 | — | — | 0 | — |
| TD Cowen | Buy | 2026-08-04 | $550 | 1 | 0 | 1 | — |
| Cantor Fitzgerald | Overweight | 2026-08-04 | $595 | 3 | 1 | 4 | 0 of 1 |
| Baird | Underperform | 2026-07-07 | $350 | — | — | 0 | — |
| Evercore ISI Group | Outperform | 2026-01-23 | $530 | 2 | 0 | 2 | 1 of 1 |
| Leerink Partners | Outperform | 2025-12-29 | $525 | 2 | 1 | 3 | 1 of 1 |
| Wells Fargo | Overweight | 2025-12-10 | $515 | 3 | 0 | 3 | 0 of 1 |
| Truist Securities | Buy | 2026-08-05 | $565 | 3 | 2 | 5 | 0 of 1 |
| Canaccord Genuity | Hold | 2026-08-04 | $442 | 4 | 0 | 4 | — |
| HC Wainwright & Co. | Buy | 2026-03-10 | $641 | 1 | 6 | 7 | 1 of 1 |
| Oppenheimer | Outperform | 2026-03-10 | $600 | 0 | 1 | 2 | — |
| Stifel | Hold | 2026-02-13 | $466 | 3 | 1 | 4 | — |
| Maxim Group | Buy | 2026-03-18 | $575 | — | — | 0 | — |
| Bank of America | Buy | 2026-03-10 | $598 | 0 | 4 | 4 | 0 of 1 |
| Citigroup | Buy | 2026-03-10 | $585 | 0 | 3 | 3 | 0 of 1 |
| Jefferies | Buy | 2026-03-10 | $580 | 0 | 0 | 1 | 0 of 1 |
| Scotiabank | Sector Perform | 2026-02-13 | $558 | 2 | 1 | 3 | — |
| Wolfe Research | Outperform | 2026-01-06 | $548 | 1 | 0 | 1 | — |
Counts for one firm on one stock are small and move together; they are a record, not a grade. Neither the firms nor VRTX carry a letter here. Why →
Every call, last 12 months
| Date | Firm | Rating | Action | Price at call | Target | Target status | Move in the 30 days before |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | RBC Capital | Outperform | maintained | $503.25 | $576 | running to 2027-10-08 | -4.8% |
| 2026-09-28 | UBS | Buy | maintained | $527.67 | $615 | running to 2027-09-28 | -2.6% |
| 2026-08-05 | Truist Securities | Buy | maintained | $484.83 | $565 | running to 2027-08-05 | -8.4% |
| 2026-08-05 | Barclays | Overweight | maintained | $484.83 | $617 | running to 2027-08-05 | -8.4% |
| 2026-08-04 | TD Cowen | Buy | maintained | $478.71 | $550 | reached 2026-08-19 | -9.3% |
| 2026-08-04 | Cantor Fitzgerald | Overweight | maintained | $478.71 | $595 | running to 2027-08-04 | -9.3% |
| 2026-08-04 | Canaccord Genuity | Hold | maintained | $478.71 | $442 | running to 2027-08-04 | -9.3% |
| 2026-07-13 | UBS | Buy | maintained | $480.25 | $585 | replaced 2026-09-28, new $615 | +7.9% |
| 2026-07-13 | Truist Securities | Buy | maintained | $480.25 | $560 | replaced 2026-08-05, new $565 | +7.9% |
| 2026-07-07 | RBC Capital | Outperform | maintained | $522.25 | $570 | replaced 2026-10-08, new $576 | +16.9% |
| 2026-07-07 | Baird | Underperform | maintained | $522.25 | $350 | running to 2027-07-07 | +16.9% |
| 2026-05-06 | Barclays | Overweight | maintained | $427.65 | $615 | replaced 2026-08-05, new $617 | -1.5% |
| 2026-05-05 | Canaccord Genuity | Hold | maintained | $424.36 | $436 | within 5% of price when set | -3.3% |
| 2026-05-05 | Morgan Stanley | Overweight | maintained | $424.36 | $616 | running to 2027-11-05 | -3.3% |
| 2026-05-05 | Bernstein | Outperform | maintained | $424.36 | $572 | running to 2027-05-05 | -3.3% |
| 2026-05-05 | RBC Capital | Outperform | maintained | $424.36 | $543 | replaced 2026-07-07, new $570 | -3.3% |
| 2026-04-30 | Canaccord Genuity | Hold | maintained | $427.38 | $437 | within 5% of price when set | -4.3% |
| 2026-04-10 | Morgan Stanley | Overweight | maintained | $436.27 | $612 | replaced 2026-05-05, new $616 | -11.4% |
| 2026-03-18 | Maxim Group | Hold → Buy | upgrade | $451.59 | $575 | running to 2027-03-18 | -8.1% |
| 2026-03-11 | Truist Securities | Buy | maintained | $492.38 | $525 | reached 2026-07-02 | +4.6% |
| 2026-03-10 | Morgan Stanley | Overweight | maintained | $499.17 | $596 | replaced 2026-04-10, new $612 | +4.5% |
| 2026-03-10 | Bank of America | Buy | maintained | $499.17 | $598 | running to 2027-03-10 | +4.5% |
| 2026-03-10 | Citigroup | Buy | maintained | $499.17 | $585 | running to 2027-03-10 | +4.5% |
| 2026-03-10 | Oppenheimer | Outperform | maintained | $499.17 | $600 | running to 2027-03-10 | +4.5% |
| 2026-03-10 | Jefferies | Buy | initiated | $499.17 | $580 | running to 2027-03-10 | +4.5% |
| 2026-03-10 | HC Wainwright & Co. | Buy | maintained | $499.17 | $641 | running to 2027-03-10 | +4.5% |
| 2026-02-17 | Canaccord Genuity | Hold | maintained | $477.32 | $441 | reached 2026-03-27 | +8.2% |
| 2026-02-17 | Barclays | Overweight | maintained | $477.32 | $607 | replaced 2026-05-06, new $615 | +8.2% |
| 2026-02-17 | HC Wainwright & Co. | Buy | maintained | $477.32 | $591 | replaced 2026-03-10, new $641 | +8.2% |
| 2026-02-13 | Scotiabank | Sector Perform | maintained | $491.47 | $558 | running to 2027-02-13 | +9.3% |
| 2026-02-13 | RBC Capital | Outperform | maintained | $491.47 | $541 | replaced 2026-05-05, new $543 | +9.3% |
| 2026-02-13 | Stifel | Hold | maintained | $491.47 | $466 | reached 2026-03-05 | +9.3% |
| 2026-02-13 | Oppenheimer | Perform → Outperform | upgrade | $491.47 | $540 | replaced 2026-03-10, new $600 | +9.3% |
| 2026-02-13 | HC Wainwright & Co. | Buy | maintained | $491.47 | $518 | replaced 2026-02-17, new $591 | +9.3% |
| 2026-01-28 | Barclays | Equal-Weight → Overweight | upgrade | $477.91 | $606 | replaced 2026-02-17, new $607 | +3.9% |
| 2026-01-26 | UBS | Buy | maintained | $476.84 | $545 | replaced 2026-07-13, new $585 | +3.0% |
| 2026-01-23 | Evercore ISI Group | Outperform | maintained | $468.41 | $530 | reached 2026-08-19 | +1.2% |
| 2026-01-22 | RBC Capital | Sector Perform → Outperform | upgrade | $467.35 | $546 | replaced 2026-02-13, new $541 | +1.8% |
| 2026-01-12 | Bernstein | Market Perform → Outperform | upgrade | $460.59 | — | no target | +1.9% |
| 2026-01-06 | Wolfe Research | Peer Perform → Outperform | upgrade | $468.38 | $548 | reached 2026-08-19 | +2.8% |
| 2025-12-29 | Leerink Partners | Outperform | maintained | $459.78 | $525 | reached 2026-07-02 | +6.0% |
| 2025-12-10 | Wells Fargo | Overweight | maintained | $444.64 | $515 | reached 2026-07-02 | +5.6% |
| 2025-12-05 | Morgan Stanley | Overweight | maintained | $455.48 | $564 | replaced 2026-03-10, new $596 | +9.2% |
| 2025-12-03 | Morgan Stanley | Equal-Weight → Overweight | upgrade | $463.13 | $516 | replaced 2025-12-05, new $564 | +8.7% |
| 2025-11-07 | UBS | Buy | maintained | $409.47 | $546 | replaced 2026-01-26, new $545 | — |
| 2025-11-04 | RBC Capital | Sector Perform | maintained | $421.67 | $415 | within 5% of price when set | — |
| 2025-11-04 | Barclays | Equal-Weight | maintained | $421.67 | $414 | within 5% of price when set | — |
| 2025-11-04 | Stifel | Hold | maintained | $421.67 | $445 | reached 2025-12-03 | — |
Also in Biotech
Interactive version with the price chart and target overlay: Scorecard tab on the dashboard. All covered names: index.
How calls are checked
Every call is checked on the firm's own terms. A price target is followed until its own deadline (12 months unless the firm publishes a different horizon) and ends as reached (the stock closed at or beyond it while it stood), replaced (the same firm set a new target first) or short at deadline. A rating is compared with the stock's sector SPDR ETF on total return over the rating's life, because most big-firm ratings are relative: Overweight means "beat its peers", not "go up". Hold-type ratings are tracked, not graded. A firm is numbered only with 30+ resolved targets, and a letter prints only for a firm's whole record where an exact test separates it from a coin flip. None of this is a verdict on anyone's skill, and one day is never a grade. The full method →
Get the daily brief
Our take, the S&P 500 Pulse, the Street's calls and today's docket — one email, weekdays, 9 AM ET, 30 minutes before the open.